A microfluidic chemotaxis device for high content screening

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44HL088785-02
Agency Tracking Number: HL088785
Amount: $963,340.00
Phase: Phase II
Program: SBIR
Awards Year: 2009
Solicitation Year: 2009
Solicitation Topic Code: N/A
Solicitation Number: PHS2009-2
Small Business Information
BELLBROOK LABS, LLC
5500 Nobel Drive, Suite 250, MADISON, WI, 53711
DUNS: 119165251
HUBZone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 IVAR MEYVANTSSON
 (608) 227-4517
 IVAR.MEYVANTSSON@BELLBROOKLABS.COM
Business Contact
 ROBERT LOWERY
Phone: (608) 227-4501
Email: bob.lowery@bellbrooklabs.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Leukocyte recruitment is central to inflammation, and there is intense focus on inhibiting the process both for chronic inflammatory disorders and for conditions where inflammation plays a contributory role, such as atherosclerosis. Whereas current anti-inflammatory drugs such as NSAIDs target secondary effects that are induced after inflammation is already established, inhibiting leukocyte recruitment would prevent the initiation of inappropriate inflammatory responses. Chemotaxis - the movement of cells aligned with a chemical gradient - is the fundamental process underlying neutrophil recruitment. Despite its importance, there are limited screening tools available for medium to high throughput analysis of leukocyte recruitment. Typically, primary screening incorporates a molecular target such as an enzyme or receptor, and hits are then validated in cumbersome in vitro cell migration assays. Existing assays suffer from three main problems: 1) Lack of repeatability (e.g. due to trapped air), 2) need for manual operations (e.g. filter removal), and 3) large cell number requirement (e.g. 1x105 cells/datum). We aim to solve each of these problems by taking advantage of microfluidic technology. In this phase II project we will establish injection molding of full plate (i.e. 96 unit) parts and adapt manufacturing methods developed under the phase I grant to produce devices that suitable for automation. We will use these devices to show reproducibility and data quality while reducing the number of cells required per datum 10-fold. Importantly we will demonstrate the use of the microfluidic chemotaxis device in a high content screening study where multi-parametric image- based analysis is applied to test both migration and polarization of primary human neutrophils. PUBLIC HEALTH RELEVANCE: The migration of cells from the bloodstream to sites of injury is one of the fundamental processes underlying chronic inflammatory disorders such as arthritis and inflammatory bowel disease. Responding cells migrate toward higher concentrations of signaling molecules that are released at the injury site. To enable the discovery of drugs to block this process, we are developing plastic devices for high throughput cell migration assays in defined chemical gradients.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government